{"id":"W4297094017","doi":"10.1200/jco.22.00533","title":"Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":162,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Sanofi Pasteur; Pharmacyclics; EMD Serono; Genentech; Aptitude Health; Qbiotics; Italfarmaco; Eli Lilly and Company; Ono Pharmaceutical; Eisai; Astellas Pharma; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Calithera Biosciences; Pfizer; Incyte; Array BioPharma; Five Prime Therapeutics; Ipsen; Clovis Oncology; Les Laboratories Pierre Fabre; Sun Pharma; Advanced Accelerator Applications; Regeneron Pharmaceuticals; Endocyte; Sanofi; GlaxoSmithKline; Amgen; Celgene; EUSA Pharma; AstraZeneca; Bristol-Myers Squibb","keywords":"Nivolumab; Medicine; Ipilimumab; Hazard ratio; Internal medicine; Adjuvant; Population; Melanoma; Adjuvant therapy; Adverse effect; Randomized controlled trial; Stage (stratigraphy); Gastroenterology; Oncology; Surgery; Cancer; Immunotherapy; Confidence interval; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002790342,0.0002723797,0.002176733,0.0003318148,0.0001003919,0.00000951573,0.0003769403,0.0002388616,0.001911282],"category_scores_gemma":[0.0004590669,0.0001670936,0.0003277627,0.0006770403,0.0004297446,0.0001508856,0.00009731777,0.001441065,0.00000198359],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006434303,"about_ca_system_score_gemma":0.00317068,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003125585,"about_ca_topic_score_gemma":0.001032541,"domain_scores_codex":[0.9945447,0.0009410884,0.002689631,0.0003403056,0.00106292,0.0004213261],"domain_scores_gemma":[0.9945627,0.001301896,0.002874519,0.0004472088,0.0005668976,0.0002467302],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7975734,0.006200812,0.1603642,0.00004243068,0.001348068,0.0008805231,0.0003333401,0.00005478774,0.0003428634,0.000008815844,0.0009012944,0.03194943],"study_design_scores_gemma":[0.2300378,0.2304605,0.5136012,0.0001166681,0.0001226052,0.00004503174,0.000723558,0.00005963738,0.0001463888,0.000004656143,0.02450391,0.0001781053],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9959553,0.0004707821,0.00001189001,0.001112314,0.00107925,0.0007502658,0.00005994549,0.00001645723,0.000543779],"genre_scores_gemma":[0.9965641,0.0006498019,0.0007258782,0.0006579944,0.0001184965,0.00002021651,0.00002749543,0.00005134317,0.001184677],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5675356,"threshold_uncertainty_score":0.9990011,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08196171607296819,"score_gpt":0.3946335868003538,"score_spread":0.3126718707273856,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}